NL8920901A - Werkwijze voor het behandelen en voorkomen van verlies van botmassa. - Google Patents

Werkwijze voor het behandelen en voorkomen van verlies van botmassa. Download PDF

Info

Publication number: NL8920901A
Authority: NL; Netherlands
Prior art keywords: vitamin; bone; osteoporosis; compound; mammals
Prior art date: 1988-08-02

Application number

NL8920901A

Other languages

English (en)

Dutch (nl)

Original Assignee

Bone Care Int Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-08-02

Filing date

1989-08-02

Publication date

1990-07-02

1989-08-02 Application filed by Bone Care Int Inc filed Critical Bone Care Int Inc

1990-07-02 Publication of NL8920901A publication Critical patent/NL8920901A/nl

Links

210000000988 bone and bone Anatomy 0.000 title claims abstract description 41
238000000034 method Methods 0.000 title claims description 25
239000011575 calcium Substances 0.000 claims abstract description 37
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 35
229910052791 calcium Inorganic materials 0.000 claims abstract description 35
229960002061 ergocalciferol Drugs 0.000 claims abstract description 34
239000011653 vitamin D2 Substances 0.000 claims abstract description 34
208000001132 Osteoporosis Diseases 0.000 claims abstract description 23
238000010521 absorption reaction Methods 0.000 claims abstract description 12
239000003814 drug Substances 0.000 claims abstract 4
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 29
150000001875 compounds Chemical class 0.000 claims description 21
229910052500 inorganic mineral Inorganic materials 0.000 claims description 19
239000011707 mineral Substances 0.000 claims description 19
229930003316 Vitamin D Natural products 0.000 claims description 18
235000019166 vitamin D Nutrition 0.000 claims description 18
239000011710 vitamin D Substances 0.000 claims description 18
229940046008 vitamin d Drugs 0.000 claims description 18
-1 Vitamin D compounds Chemical class 0.000 claims description 16
239000003795 chemical substances by application Substances 0.000 claims description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
229940088597 hormone Drugs 0.000 claims description 8
239000005556 hormone Substances 0.000 claims description 8
208000001685 postmenopausal osteoporosis Diseases 0.000 claims description 7
229940069978 calcium supplement Drugs 0.000 claims description 5
206010039984 Senile osteoporosis Diseases 0.000 claims description 4
FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 4
230000009245 menopause Effects 0.000 claims description 4
229940122361 Bisphosphonate Drugs 0.000 claims description 3
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 3
102000055006 Calcitonin Human genes 0.000 claims description 3
108060001064 Calcitonin Proteins 0.000 claims description 3
MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims description 3
150000004663 bisphosphonates Chemical class 0.000 claims description 3
229910052796 boron Inorganic materials 0.000 claims description 3
229960004015 calcitonin Drugs 0.000 claims description 3
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 3
229940035811 conjugated estrogen Drugs 0.000 claims description 3
208000035475 disorder Diseases 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 3
235000001892 vitamin D2 Nutrition 0.000 claims description 3
MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
231100000252 nontoxic Toxicity 0.000 claims description 2
230000003000 nontoxic effect Effects 0.000 claims description 2
239000000243 solution Substances 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims 8
235000010755 mineral Nutrition 0.000 claims 6
239000008194 pharmaceutical composition Substances 0.000 claims 3
241000282412 Homo Species 0.000 claims 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
239000004480 active ingredient Substances 0.000 claims 2
239000003053 toxin Substances 0.000 claims 2
231100000765 toxin Toxicity 0.000 claims 2
238000010255 intramuscular injection Methods 0.000 claims 1
238000010253 intravenous injection Methods 0.000 claims 1
239000011780 sodium chloride Substances 0.000 claims 1
229960002668 sodium chloride Drugs 0.000 claims 1
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical class [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims 1
235000013024 sodium fluoride Nutrition 0.000 claims 1
238000010254 subcutaneous injection Methods 0.000 claims 1
239000011647 vitamin D3 Substances 0.000 abstract description 22
229940021056 vitamin d3 Drugs 0.000 abstract description 22
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 abstract description 13
230000009102 absorption Effects 0.000 abstract description 10
230000000968 intestinal effect Effects 0.000 abstract description 7
231100000419 toxicity Toxicity 0.000 abstract description 7
230000001988 toxicity Effects 0.000 abstract description 7
208000037147 Hypercalcaemia Diseases 0.000 abstract description 6
230000000148 hypercalcaemia Effects 0.000 abstract description 6
208000030915 hypercalcemia disease Diseases 0.000 abstract description 6
206010020590 Hypercalciuria Diseases 0.000 abstract description 5
229930194270 alpha-Vitamin Natural products 0.000 abstract description 5
230000004936 stimulating effect Effects 0.000 abstract description 4
230000009103 reabsorption Effects 0.000 abstract 1
210000002966 serum Anatomy 0.000 description 12
235000005282 vitamin D3 Nutrition 0.000 description 11
150000003710 vitamin D derivatives Chemical class 0.000 description 9
201000010099 disease Diseases 0.000 description 7
230000000694 effects Effects 0.000 description 7
239000000902 placebo Substances 0.000 description 7
229940068196 placebo Drugs 0.000 description 7
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
208000029725 Metabolic bone disease Diseases 0.000 description 5
102000004067 Osteocalcin Human genes 0.000 description 5
108090000573 Osteocalcin Proteins 0.000 description 5
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
230000037182 bone density Effects 0.000 description 4
235000005911 diet Nutrition 0.000 description 4
208000005368 osteomalacia Diseases 0.000 description 4
230000002485 urinary effect Effects 0.000 description 4
208000000038 Hypoparathyroidism Diseases 0.000 description 3
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
229940109239 creatinine Drugs 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
231100001231 less toxic Toxicity 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
229910052698 phosphorus Inorganic materials 0.000 description 3
239000011574 phosphorus Substances 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
208000020084 Bone disease Diseases 0.000 description 2
208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 2
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
108010081690 Pertussis Toxin Proteins 0.000 description 2
230000001773 anti-convulsant effect Effects 0.000 description 2
239000001961 anticonvulsive agent Substances 0.000 description 2
229960003965 antiepileptics Drugs 0.000 description 2
238000007470 bone biopsy Methods 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
230000037213 diet Effects 0.000 description 2
230000000378 dietary effect Effects 0.000 description 2
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
229960002591 hydroxyproline Drugs 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
230000011164 ossification Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
201000006409 renal osteodystrophy Diseases 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
208000013038 Hypocalcemia Diseases 0.000 description 1
206010058359 Hypogonadism Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000030984 MIRAGE syndrome Diseases 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
206010049088 Osteopenia Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241000700159 Rattus Species 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
230000033558 biomineral tissue development Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
235000021152 breakfast Nutrition 0.000 description 1
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
230000004094 calcium homeostasis Effects 0.000 description 1
230000003913 calcium metabolism Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000009535 clinical urine test Methods 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
208000021864 drug-induced osteoporosis Diseases 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
230000005802 health problem Effects 0.000 description 1
208000031424 hyperprolactinemia Diseases 0.000 description 1
230000000705 hypocalcaemia Effects 0.000 description 1
230000003553 hypophosphatemic effect Effects 0.000 description 1
201000000916 idiopathic juvenile osteoporosis Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
TVLSRXXIMLFWEO-UHFFFAOYSA-N prochloraz Chemical compound C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl TVLSRXXIMLFWEO-UHFFFAOYSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000036325 urinary excretion Effects 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pretreatment Of Seeds And Plants (AREA)
Processing Of Solid Wastes (AREA)
Crystals, And After-Treatments Of Crystals (AREA)
Disintegrating Or Milling (AREA)
Fertilizers (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NL8920901A 1988-08-02 1989-08-02 Werkwijze voor het behandelen en voorkomen van verlies van botmassa. NL8920901A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22737188A	1988-08-02	1988-08-02
US22737188		1988-08-02

Publications (1)

Publication Number	Publication Date
NL8920901A true NL8920901A (nl)	1990-07-02

Family

ID=22852835

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8920901A NL8920901A (nl)	1988-08-02	1989-08-02	Werkwijze voor het behandelen en voorkomen van verlies van botmassa.

Country Status (11)

Country	Link
EP (1)	EP0381750B1 (de)
JP (1)	JP3030854B2 (de)
AT (1)	ATE114471T1 (de)
AU (1)	AU634490B2 (de)
CA (1)	CA1341408C (de)
DE (1)	DE68919673T2 (de)
GB (1)	GB2231794B (de)
MX (1)	MX9203760A (de)
NL (1)	NL8920901A (de)
SE (1)	SE9001308L (de)
WO (1)	WO1990001321A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7056882B2 (en)	1991-03-11	2006-06-06	Curis, Inc.	Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
JPH0753384A (ja) *	1993-07-13	1995-02-28	Wisconsin Alumni Res Found	２４−エピ−１α−ヒドロキシビタミンＤ２を含んでなる骨粗鬆症治療剤
US5763429A (en) *	1993-09-10	1998-06-09	Bone Care International, Inc.	Method of treating prostatic diseases using active vitamin D analogues
IL115241A (en) *	1994-09-26	2000-08-31	American Cyanamid Co	Calcium dietary supplement
US6376479B1 (en)	1995-04-03	2002-04-23	Bone Care International, Inc.	Method for treating and preventing hyperparathyroidism
US20020183288A1 (en) *	1995-04-03	2002-12-05	Bone Care International, Inc.	Method for treating and preventing hyperparathyroidism
US6096876A (en) *	1997-08-06	2000-08-01	Shriners Hospitals For Children	1-α-hydroxylase materials and methods
US20060270640A1 (en) *	2004-02-18	2006-11-30	Mercian Corporation	Method of preventing, medicating, and/or treating hypocalcemia of domestic mammal
US7094775B2 (en)	2004-06-30	2006-08-22	Bone Care International, Llc	Method of treating breast cancer using a combination of vitamin D analogues and other agents
DK2148684T3 (da) *	2007-04-25	2013-04-22	Cytochroma Inc	Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4225596A (en) *	1978-10-13	1980-09-30	Wisconsin Alumni Research Foundation	Method for treating calcium imbalance and improving calcium absorption in mammals
DE3448360C2 (de) *	1983-05-09	1991-10-02	Wisconsin Alumni Res Found
US4588716A (en)	1984-05-04	1986-05-13	Wisconsin Alumni Research Foundation	Method for treating metabolic bone disease in mammals
IL78342A (en) *	1985-04-04	1991-06-10	Gen Hospital Corp	Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US5104864A (en) *	1988-08-02	1992-04-14	Bone Care International, Inc.	Method for treating and preventing loss of bone mass

1988
- 1988-11-15 CA CA000583162A patent/CA1341408C/en not_active Expired - Fee Related
1989
- 1989-08-02 AU AU42203/89A patent/AU634490B2/en not_active Ceased
- 1989-08-02 DE DE68919673T patent/DE68919673T2/de not_active Expired - Fee Related
- 1989-08-02 EP EP89910341A patent/EP0381750B1/de not_active Expired - Lifetime
- 1989-08-02 NL NL8920901A patent/NL8920901A/nl not_active Application Discontinuation
- 1989-08-02 AT AT89910341T patent/ATE114471T1/de not_active IP Right Cessation
- 1989-08-02 JP JP1509666A patent/JP3030854B2/ja not_active Expired - Fee Related
- 1989-08-02 WO PCT/US1989/003341 patent/WO1990001321A2/en not_active Ceased
1990
- 1990-03-28 GB GB9006990A patent/GB2231794B/en not_active Expired - Fee Related
- 1990-04-10 SE SE9001308A patent/SE9001308L/ not_active Application Discontinuation
1992
- 1992-06-29 MX MX9203760A patent/MX9203760A/es unknown

Also Published As

Publication number	Publication date
EP0381750A1 (de)	1990-08-16
JP3030854B2 (ja)	2000-04-10
DE68919673T2 (de)	1995-06-01
GB2231794B (en)	1992-01-15
WO1990001321A2 (en)	1990-02-22
DE68919673D1 (de)	1995-01-12
MX9203760A (es)	1992-09-01
SE9001308D0 (sv)	1990-04-10
EP0381750B1 (de)	1994-11-30
AU634490B2 (en)	1993-02-25
CA1341408C (en)	2002-12-10
ATE114471T1 (de)	1994-12-15
GB2231794A (en)	1990-11-28
GB9006990D0 (en)	1990-08-29
SE9001308L (sv)	1990-04-10
JPH03501388A (ja)	1991-03-28
AU4220389A (en)	1990-03-05
WO1990001321A3 (en)	1990-05-17

Legal Events

Date	Code	Title	Description
1995-04-03	BV	The patent application has lapsed

Publication	Publication Date	Title
US5403831A (en)	1995-04-04	Method of treating and preventing loss of bone mass using 1α-hydroxy-vitamin D2
CA2217260C (en)	2000-08-01	Use of vitamin d2 or vitamin d4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
US5869473A (en)	1999-02-09	Method for treating and preventing hyperparathyroidism
ES2368824T3 (es)	2011-11-22	Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos.
Nowson et al.	2004	Vitamin D in Australia: issues and recommendations
US20090137536A1 (en)	2009-05-28	Method for treating and preventing hyperparathyroidism
US6376479B1 (en)	2002-04-23	Method for treating and preventing hyperparathyroidism
Chines et al.	1990	Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature
NL8920901A (nl)	1990-07-02	Werkwijze voor het behandelen en voorkomen van verlies van botmassa.
Okumura et al.	1987	Effect of 1α-hydroxyvitamin D3 on osteoporosis induced by immobilization combined with ovariectomy in rats
Gimenez et al.	1982	Prevention of phosphate-induced progression of uremia in rats by 3-phosphocitric acid
US6489361B1 (en)	2002-12-03	Phosphorus binder
Coburn et al.	1991	Oral and Parenteral Calcitriol for the Management of End-Stage Renal Disease¹
Deroisy et al.	1998	Effects of two 1-year calcium and vitamin D3 treatments on bone remodeling markers and femoral bone density in elderly women
NZ203251A (en)	1986-04-11	Pharmaceutical compositions containing 1alpha,25,26-trihydroxycholecalciferol
Pierides et al.	1977	1, 25-dihydroxycholecalciferol in renal osteodystrophy. Epiphysiolysis--anticonvulsant therapy.
US5942502A (en)	1999-08-24	Method of treating diseases resulting from calcium metabolism disorders
KR20000075514A (ko)	2000-12-15	9,10-세코콜레스타-5,7,10(19)-트리엔-1,3-디올 또는 알파칼시돌
HK1008180B (en)	2004-02-20	Use of vitamin d 2 or vitamin d 4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
Caniggia et al.	1996	Efficacy and safety of long-term, open-label treatment with calcitriol in postmenopausal osteoporosis: a retrospective analysis
WOMEN et al.	0	EFFECTS OF TWO 1-YEAR CALCIUM AND VITAMIN D
Llach	1991	Treatment of Secondary Hyperparathyroidism by Intravenous Calcitriol